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Deep brain stimulation (DBS) is considered as a treatment option
for many neurological diseases. Many patients with movement
disorders exhibit remarkable improvement after DBS. Owing to its
minimally invasive nature, reversibility, and adjustability, DBS has

© The authors 2019. This article is published with
open access at journals.sagepub.com/home/BSA

been increasingly used over the past several decades. Dystonia is
one of the most common movement disorders among children, and
there is no effective treatment. Recently, some surgeon groups have
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performed DBS surgery for children. However, the outcomes of
DBS in children are not well characterized. Here we mainly discuss
the efficacy of DBS against childhood‐onset dystonia and introduce
the main procedure of pediatric DBS based on our own experience.
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1

Introduction

The first documented deep brain stimulation (DBS)
procedure was performed by Benabid et al in
1987 to treat a patient with Parkinson’s disease
(PD) [1]. Subsequently, DBS has been used to
treat numerous neurological disorders. To date,
the US Food and Drug Administration (FDA)
has approved the use of DBS for treating PD,
essential tremor, obsessive‐compulsive disorder,
and dystonia. In addition, the use of DBS for the
treatment of refractory epilepsy was approved

in Europe in 2010 [2]. An increasing number of
researchers are investigating the use of DBS for
the treatment of other diseases, such as chronic
pain, Alzheimer’s disease, depression, and Tourette
syndrome. The therapeutic efficacy of DBS is
comparable with that of traditional surgeries; in
addition, DBS offers the advantage of adjustability
of stimulation and reversibility of any adverse
effects. Although DBS has been widely used, the
mechanisms underlying its therapeutic efficacy
remain poorly understood. Several hypotheses
have been proposed in this respect [3], such as
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the “classic rate model” “jamming theory” and
“bursting”.
The technological innovations and scientific
advances in the past several decades have led to
a rapid increase in the applications and studies
of DBS. However, despite the great advantages
of DBS in the treatment of movement disorders,
its use in children remains relatively rare. The
Peking University First Hospital (PKUFH) is one
of the organizations that pioneered the use of
DBS in children with dystonia in China. To date,
more than a dozen children with dystonia have
been treated using DBS by the surgical group for
pediatric movement disorders at the PKUFH.
Dystonia is a neurological disorder characterized
by sustained or intermittent muscle contractions
that results in abnormal, involuntary twisting
movements or postures [4, 5]. Dystonia is one of
the most common movement disorders among
children; the disorder has negative impacts on
growth and development, daily activities, and
school performance. There are many causes of
dystonia, including genetic mutations, cerebral
palsy (CP), and inherited metabolic diseases.
Currently, there is no cure for dystonia; the results
of pharmacological management appear to be
unsatisfactory. Owing to the rapid development
and widespread application of DBS, surgeons have
used this minimally invasive surgery to treat
patients with dystonia and have been successful
to some extent. Ever since Coubes et al. first used
DBS for the treatment of dystonia [6], it has been
gradually accepted as an optional treatment for
childhood dystonia. Interestingly, children with
DYT1 dystonia respond particularly well to DBS,
with greater improvement than non‐DYT1 patients
[7]. However, owing to the limited documented
experience on DBS for childhood dystonia, the
role of DBS in other types of dystonia remains
unclear.
In this review, we discuss the role of DBS in

the treatment of dystonia and describe our
experience with DBS for the management of
childhood dystonia.

2

DBS for dystonia

Clinically, dystonia is mainly classified according
to three criteria, i.e., etiology, age at onset, and
body distribution [8]. The most widely accepted
classification in the literature categorizes dystonia
into two main types [9]: primary dystonia (dystonia
is the only clinical sign and includes idiopathic
or genetic disorders with no neuropathological
abnormalities) and secondary dystonia [dystonia
arising from neurodegeneration, acquired causes
(such as lesions within the brain), or genetic
conditions with a progressive course]. Although
the recently published consensus classification
provides a more detailed approach to distinguish
dystonia [10], few published articles have used
this classification.
2.1 Primary dystonia
There is a consensus that DBS is safe and effective
for the treatment of primary dystonia in children
[5, 11]. To date, 29 types of dystonia caused by
monogenic mutations are recognized (DYT1–
DYT29) [9, 12]; of these, the initial symptoms of
DYT1–6, 11, 12, and 25–29 are noticeable during
childhood or early adulthood. DBS has been used
as an alternative treatment for several types of
DYTs (Table 1).
DYT1 was the first discovered primary dystonia
and is caused by the torsin‐1A (TOR1A) gene,
and it is the most commonly reported primary
dystonia treated using DBS [13, 14]. Patients
with DYT1 typically present with dystonia since
childhood or adolescence; the condition initially
affects a single limb and often progresses to general
dystonia within 1~3 years. According to some
reports, DYT1 appears to show the best response
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Table 1 Effect of DBS in patients with early‐onset primary dystonia.
Dystonia type

Pathogenic gene

Effect of DBS

References

DYT1

TOR1A

More than 90% patients showed improvement after DBS

[14, 15]

DYT6

THAP1

Approximately 60% patients showed improvement after surgery

[16–20]

DYT11

SCGE

Improvement was reported in sporadic cases

[23–25]

DYT12

ATP1A3

No improvement was noted

[27–31]

DYT26

KCDT17

Improvement was reported in sporadic cases

[32, 33]

DYT28

KMT2B

All patients showed clinical benefits

[24–37]

to DBS among all dystonia types. Approximately
90% patients with DYT1 who underwent DBS
experienced an average improvement of 60% in
the 1st year after surgery, as assessed using the
Burke–Fahn–Marsden Dystonia Rating Scale
(BFMDRS) [14, 15].
DYT6 usually presents with dysphonia or
writer’s cramp during late childhood or adolescence,
and approximately 25% patients gradually develop
craniocervical involvement. THAP domain‐
containing protein 1 (THAP1) gene is the
pathogenic gene of DYT6. Numerous cases of
patients with DYT6 who underwent DBS surgery
have been reported [16–20]; the therapeutic efficacy
was not as good as that observed in patients
with DYT1 [14, 15]. Only 60% of patients with
DYT6 experienced an average improvement of
30% in the first year following DBS, as assessed
using BFMDRS.
DYT11, also known as myoclonus‐dystonia, is
characterized by the involvement of the neck or
arms/hands during childhood or early adulthood.
The condition has an autosomal dominant
inheritance with pathogenic mutations in the
sarcoglycan epsilon (SCGE) gene. Alcohol tends
to relieve myoclonus to a large extent [21], and
some drugs, such as zonisamide, may ameliorate
the symptoms [22]. In addition, several research
groups have reported that patients with DYT11
also respond to DBS [23–25]. DBS could be an
optional treatment for some refractory cases
because it may result in 50% improvement.

http://bsa.tsinghuajournals.com

DYT12 is characterized by sudden‐onset
dystonia–parkinsonism during adolescence or
early adulthood; ATPase Na+/K+ transporting
subunit alpha 3 (ATP1A3) is the causative gene
for this disorder [26]. Several reports have
described trials of DBS in patients with DYT12;
however, none of the patients showed satisfactory
clinical effects [27–31].
DYT26 is characterized by motor delay, onset
of myoclonic jerks mainly affecting the neck and
upper limbs, and progression to dystonia [32–33].
In 2015, the gene encoding potassium channel
tetramerization domain‐containing 17 (KCDT17)
was shown to be associated with this type of
dystonia [32]. An excellent response to DBS was
reported [33].
DYT28 is caused by pathogenic mutations of
the lysine specific methyltransferase 2B (KMT2B)
gene. The characteristic feature of this disorder
is childhood‐onset generalized dystonia. More
than a dozen patients with DYT28 reportedly
showed clinical response to DBS [34–37]. Younger
patients with DYT28 showed improved responses
to DBS, and some of them regained the ability to
walk without support after surgery.
DYT3 and DYT25 typically present during late
adulthood; however, some cases may present
earlier [14]. Several reports have demonstrated
that patients with DYT3 and DYT25 respond to
DBS [38–41]. However, DYT2, DYT4, DYT27, and
DYT29 seem to be extremely rare entities, and
we were unable to find any definitive evidence
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documented unsatisfactory results of DBS in
patients with such types of acquired dystonia [5].

of their responses to DBS.
2.2 Secondary dystonia
The most common causes of secondary dystonia
include CP, pantothenate kinase‐associated neuro‐
degeneration (PKAN), and inherited metabolic
diseases. In this section, we mainly discuss the
efficacy of DBS for the treatment of patients with
CP, PKAN, and glutaric aciduria type 1 (GA1).
Patients with CP exhibit four major types of
motor dysfunction, including spastic, dyskinetic,
ataxic, and mixed [42]; among these, dyskinetic
CP is one of the most common causes of early‐
onset dystonia. Multiple research groups have
performed DBS in patients with dyskinetic CP;
however, the clinical results were inconsistent.
In a recent meta‐analysis of data of 59 patients
with CP, the median postoperative improvement
in BFMDRS motor and disability subscale scores
was 11.1% and 3.5%, respectively [11]. However,
Romito et al. reported good long‐term (up to 6
years after DBS) effects of DBS in patients with
dyskinetic CP (approximately 50% improvement
at the last follow‐up) [43].
PKAN is a rare autosomal recessive disorder
caused by pathogenic mutations of the panto‐
thenate kinase 2 (PANK2) gene. The main clinical
manifestations of PKAN are childhood dystonia,
dysarthria, rigidity, and an “eye‐of‐tiger” sign
on MRI. Only a few reports have described the
use of DBS in patients with PKAN, with some
degree of improvement [44, 45].
GA1 is an inherited metabolic disease caused by
the Glutaryl‐CoA dehydrogenase (GCDH) gene.
Several reports have focused on the efficacy of DBS
against GA1. To date, approximately 10 patients
with GA1 have undergone DBS [46–50], and no
obvious improvement was achieved after surgery.
In addition, disorders such as kernicterus and
Lesch–Nyhan disease (LND) may also present
with acquired dystonia. A few case reports have

3

DBS management for childhood dystonia

DBS surgery in children is very different from that
in adults. Herein, we discuss the procedure for
DBS in children and introduce some of our own
experiences (Fig. 1).
3.1 Preoperative preparation
First, we seek to determine the etiology of dystonia
as a collaborative effort involving the departments
of pediatrics and pediatric surgery. For patients
with no clear cause of dystonia, we recommend
whole‐exome sequencing or panel sequencing to
identify the underlying diseases and help predict
the efficacy of DBS. Subsequently, pediatric doctors
and pediatric surgeons collaboratively discuss
whether DBS should be performed in that patient.
If surgery is decided upon, preoperative evaluation

Fig. 1

The procedure of pediatric DBS at our center.
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of dystonia severity is performed using BFMDRS;
in addition, a video recording of the patient’s status
is saved. Unlike adults, children are unable to
accurately express the postoperative changes;
therefore, a more detailed assessment should be
performed.
3.2 Surgical procedure
Preoperative MR images are required for target
localization, and a professional workstation is
used for image infusion and surgical planning.
Unlike in adults, in children, DBS is always per‐
formed under general anesthesia with endotracheal
intubation [50]. The leads and pulse generator
are placed at the appropriate sites, as described
previously [48]. The US FDA has approved globus
pallidus internus (GPi) as a target for pediatric
DBS [14]. However, a recent study has shown
that the subthalamic nucleus (STN) could also
be an effective target for DBS for patients with
dystonia [51]. CT is performed after surgery to
verify the precise location of the lead.
3.3 Programming and postoperative evaluation
DBS programming at our institution typically
starts 1 week postoperatively, after confirmation
of the lead position by CT. Patients are instructed
to stay at the hospital for approximately 7 days
after the surgery to facilitate regular monitoring
of wound healing and any adverse events. Routine
follow‐up, comprising neurological examination,
dystonia severity evaluation, and programming,
is performed at 1, 3, and 6 months after surgery.
Subsequently, all patients are reassessed every 6
months. Based on the feedback from patients
or their parents, the stimulation parameters are
adjusted to achieve better clinical outcomes or
to reduce the adverse events. Furthermore, the
patients have access to a remote control system
for adjustment via the internet. Moreover, because
pediatric DBS is often performed in patients with

http://bsa.tsinghuajournals.com

general dystonia, postoperative rehabilitation
training is also recommended for these patients.

4

Conclusion

In this review, we discussed the efficacy of DBS
against various types of early‐onset dystonia. The
majority of patients with primary dystonia show
good response to DBS; however, additional
evidence is required to confirm the efficacy of
DBS in patients with secondary dystonia. To
the best of our knowledge, most patients with
secondary dystonia show poor response to DBS.
However, several reports have indicated that the
clinical effects tend to be unstable in the early
postoperative period; therefore, there is a need
to monitor the long‐term effects of DBS in these
patients. Additionally, based on our own exper‐
iences, we briefly introduced the main procedure
for DBS performed in children, which is slightly
different from that performed in adults.
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